Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Open Label Study to Assess the Safety and Efficacy of Sequential Administration of P1101 and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection

NCT04638439 is registered in ClinicalTrials.gov with PharmaEssentia as lead sponsor.

NCT NCT04638439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04638439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Open Label Study to Assess the Safety and Efficacy of Sequential Administration of P1101 and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
Lead sponsor
PharmaEssentia
Phase
Phase 1
Overall status
Completed
Start date
August 17, 2022
Completion date
April 8, 2026
Enrollment
20 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b infection, chronic hepatitis d infection